Skip to main content

Table 2 Patient demographics and clinical characteristics in the 20-study pool

From: Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

Characteristic, n (%)

All SAXA

Control

(n = 5701)

(n = 3455)

Age, y

  

  <65

4681 (82.1)

2766 (80.1)

  ≥65

1020 (17.9)

689 (19.9)

  ≥75

132 (2.3)

91 (2.6)

Women

2899 (50.9)

1696 (49.1)

Race

  

  White

3707 (65.0)

2034 (58.9)

  Asian

1319 (23.1)

1001 (29.0)

  Black

217 (3.8)

102 (3.0)

  Other

458 (8.0)

318 (9.2)

BMI, kg/m2

  

  <30

2914 (51.1)

1888 (54.6)

  ≥30

2780 (48.8)

1564 (45.3)

  Not reported

7 (0.1)

3 (<0.1)

Duration of T2DM, y

  

  ≤1.5

2129 (37.3)

1076 (31.1)

  ≤3

2817 (49.4)

1558 (45.1)

  >3– < 5

776 (13.6)

523 (15.1)

  ≥5

2107 (37.0)

1373 (39.7)

  ≥10

834 (14.6)

582 (16.8)

  Not reported

1 (<0.1)

1 (<0.1)

Creatinine clearance, mL/min

  

  <30

37 (0.6)

41 (1.2)

  30– < 50

90 (1.6)

68 (2.0)

  50–80

973 (17.1)

658 (19.0)

  >80

4598 (80.7)

2685 (77.7)

  Not reported

3 (<0.1)

3 (<0.1)

  1. BMI = body mass index; SAXA = saxagliptin; T2DM = type 2 diabetes mellitus.